Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients

Naoki Washida, Shuji Inoue, Takahiro Kasai, Keisuke Shinozuka, Koji Hosoya, Kohkichi Morimoto, Shu Wakino, Koichi Hayashi, Hiroshi Itoh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

New erythropoiesis-stimulating agents with a longer half-life have been developed for the treatment of anemia in patients with end-stage renal disease. This study evaluated the efficacy of darbepoetin alfa (DA) and long-acting epoetin beta pegol (continuous erythropoietin receptor activator, CERA) in patients on peritoneal dialysis (PD). Twenty-nine patients who had undergone PD for at least 6 months and were iron replacement-naïve and negative for inflammatory parameters were enrolled. Hemoglobin (Hgb) levels and blood pressure were evaluated before and after switching from DA to CERA. Percent transferrin saturation (TSAT), serum ferritin levels and blood pressure were also assessed. Twenty-eight patients were subject to the analysis, excluding one patient with a decrease in Hgb by ≥10%. Switching from DA to CERA did not alter Hgb levels. The doses of DA and CERA after 12 month treatment of each agent were 118.48±79.63 and 89.88±47.50μg/4 weeks, respectively (conversion ratio, 1:0.76). The CERA dose administered during the final 6 months was abated, compared with that given during the initial 6 months (P=0.035). The frequency of CERA injection over a 12-month period was less than that of DA (10.0±3.0 vs. 16.4±5.0, P

Original languageEnglish
Pages (from-to)450-456
Number of pages7
JournalTherapeutic Apheresis and Dialysis
Volume19
Issue number5
DOIs
Publication statusPublished - 2015 Oct 1

Fingerprint

Peritoneal Dialysis
Iron
Blood Pressure
Hemoglobins
Hematinics
Transferrin
Ferritins
continuous erythropoietin receptor activator
Darbepoetin alfa
Chronic Kidney Failure
Half-Life
Anemia
Injections
Therapeutics
Serum

Keywords

  • Blood pressure
  • Darbepoetin alfa
  • Epoetin beta pegol
  • Iron utilization

ASJC Scopus subject areas

  • Hematology
  • Nephrology

Cite this

Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients. / Washida, Naoki; Inoue, Shuji; Kasai, Takahiro; Shinozuka, Keisuke; Hosoya, Koji; Morimoto, Kohkichi; Wakino, Shu; Hayashi, Koichi; Itoh, Hiroshi.

In: Therapeutic Apheresis and Dialysis, Vol. 19, No. 5, 01.10.2015, p. 450-456.

Research output: Contribution to journalArticle

Washida, Naoki ; Inoue, Shuji ; Kasai, Takahiro ; Shinozuka, Keisuke ; Hosoya, Koji ; Morimoto, Kohkichi ; Wakino, Shu ; Hayashi, Koichi ; Itoh, Hiroshi. / Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients. In: Therapeutic Apheresis and Dialysis. 2015 ; Vol. 19, No. 5. pp. 450-456.
@article{2e57cb95046340c8ab6ce49c8998c0aa,
title = "Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients",
abstract = "New erythropoiesis-stimulating agents with a longer half-life have been developed for the treatment of anemia in patients with end-stage renal disease. This study evaluated the efficacy of darbepoetin alfa (DA) and long-acting epoetin beta pegol (continuous erythropoietin receptor activator, CERA) in patients on peritoneal dialysis (PD). Twenty-nine patients who had undergone PD for at least 6 months and were iron replacement-na{\"i}ve and negative for inflammatory parameters were enrolled. Hemoglobin (Hgb) levels and blood pressure were evaluated before and after switching from DA to CERA. Percent transferrin saturation (TSAT), serum ferritin levels and blood pressure were also assessed. Twenty-eight patients were subject to the analysis, excluding one patient with a decrease in Hgb by ≥10{\%}. Switching from DA to CERA did not alter Hgb levels. The doses of DA and CERA after 12 month treatment of each agent were 118.48±79.63 and 89.88±47.50μg/4 weeks, respectively (conversion ratio, 1:0.76). The CERA dose administered during the final 6 months was abated, compared with that given during the initial 6 months (P=0.035). The frequency of CERA injection over a 12-month period was less than that of DA (10.0±3.0 vs. 16.4±5.0, P",
keywords = "Blood pressure, Darbepoetin alfa, Epoetin beta pegol, Iron utilization",
author = "Naoki Washida and Shuji Inoue and Takahiro Kasai and Keisuke Shinozuka and Koji Hosoya and Kohkichi Morimoto and Shu Wakino and Koichi Hayashi and Hiroshi Itoh",
year = "2015",
month = "10",
day = "1",
doi = "10.1111/1744-9987.12306",
language = "English",
volume = "19",
pages = "450--456",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients

AU - Washida, Naoki

AU - Inoue, Shuji

AU - Kasai, Takahiro

AU - Shinozuka, Keisuke

AU - Hosoya, Koji

AU - Morimoto, Kohkichi

AU - Wakino, Shu

AU - Hayashi, Koichi

AU - Itoh, Hiroshi

PY - 2015/10/1

Y1 - 2015/10/1

N2 - New erythropoiesis-stimulating agents with a longer half-life have been developed for the treatment of anemia in patients with end-stage renal disease. This study evaluated the efficacy of darbepoetin alfa (DA) and long-acting epoetin beta pegol (continuous erythropoietin receptor activator, CERA) in patients on peritoneal dialysis (PD). Twenty-nine patients who had undergone PD for at least 6 months and were iron replacement-naïve and negative for inflammatory parameters were enrolled. Hemoglobin (Hgb) levels and blood pressure were evaluated before and after switching from DA to CERA. Percent transferrin saturation (TSAT), serum ferritin levels and blood pressure were also assessed. Twenty-eight patients were subject to the analysis, excluding one patient with a decrease in Hgb by ≥10%. Switching from DA to CERA did not alter Hgb levels. The doses of DA and CERA after 12 month treatment of each agent were 118.48±79.63 and 89.88±47.50μg/4 weeks, respectively (conversion ratio, 1:0.76). The CERA dose administered during the final 6 months was abated, compared with that given during the initial 6 months (P=0.035). The frequency of CERA injection over a 12-month period was less than that of DA (10.0±3.0 vs. 16.4±5.0, P

AB - New erythropoiesis-stimulating agents with a longer half-life have been developed for the treatment of anemia in patients with end-stage renal disease. This study evaluated the efficacy of darbepoetin alfa (DA) and long-acting epoetin beta pegol (continuous erythropoietin receptor activator, CERA) in patients on peritoneal dialysis (PD). Twenty-nine patients who had undergone PD for at least 6 months and were iron replacement-naïve and negative for inflammatory parameters were enrolled. Hemoglobin (Hgb) levels and blood pressure were evaluated before and after switching from DA to CERA. Percent transferrin saturation (TSAT), serum ferritin levels and blood pressure were also assessed. Twenty-eight patients were subject to the analysis, excluding one patient with a decrease in Hgb by ≥10%. Switching from DA to CERA did not alter Hgb levels. The doses of DA and CERA after 12 month treatment of each agent were 118.48±79.63 and 89.88±47.50μg/4 weeks, respectively (conversion ratio, 1:0.76). The CERA dose administered during the final 6 months was abated, compared with that given during the initial 6 months (P=0.035). The frequency of CERA injection over a 12-month period was less than that of DA (10.0±3.0 vs. 16.4±5.0, P

KW - Blood pressure

KW - Darbepoetin alfa

KW - Epoetin beta pegol

KW - Iron utilization

UR - http://www.scopus.com/inward/record.url?scp=84945438274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945438274&partnerID=8YFLogxK

U2 - 10.1111/1744-9987.12306

DO - 10.1111/1744-9987.12306

M3 - Article

C2 - 25944557

AN - SCOPUS:84945438274

VL - 19

SP - 450

EP - 456

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

IS - 5

ER -